NeoPharm, Inc.

NeoPharm, Inc.

NeoPharm, Inc. was founded in 1990 and is headquartered in Lake Bluff, Illinois. NeoPharm, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases primarily in the United States. Its products include LEP-ETU, which is in Phase II trial for the treatment of breast and ovarian cancer; LE-DT that is in Phase I trial for the treatment of various forms of cancer; and LE-rafAON, which completed preclinical studies to treat pancreatic cancer. The company has a co-operative research and development agreement with the National Institute of Neurological Diseases and Stroke for research on a therapeutic agent for untreatable brain diseases in humans. NeoPharm would provide its proprietary drug, Cintredekin Besudotox (IL13-PE38QQR), and technical resources to study its effects in various brain cancers in humans. Its IL13-PE38QQR also completed preclinical studies for the treatment of idiopathic pulmonary fibrosis and asthma. The company was formerly known as OncoMed, Inc. and changed its name to NeoPharm, Inc. in March 1995.

Contact Details

Office Address

NeoPharm, Inc.
101 Waukegan Rd., Suite 970
Lake Bluff, IL, USA 60044
Phone: (847) 887-0800
Fax: (847) 406-1764

Executives

Exec. VP of R&D

Dr. Shahid Ali

Co-Founder & Chief Exec. Officer

Dr. Aquilur Rahman

Business Reviews for NeoPharm, Inc.

Related Companies